(Q34808070)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

main subject

chronic myeloid leukemia

0 references

leukemia

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Richard A. Larson

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

F J Giles

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

G Rosti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

D-W Kim

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

R Bhatia

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

A Bosly

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

S Goldberg

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

G L S Kam

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

M Jagasia

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

W Mendrek

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

T Fischer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

T Facon

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

U Dünzinger

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

D Marin

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

M C Mueller

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Y Shou

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

N J Gallagher

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

F-X Mahon

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

M Baccarani

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

J Cortes

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

H M Kantarjian

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

3 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

1299-1301

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2010.110

4 February 2020

exact match

0 references

cites work

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078756

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078756

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078756

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078756

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

8 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.110

Chronic myeloid leukemia: reversing the chronic phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.110

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.110

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.110

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20520639

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20520639

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/LEU.2010.110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

4 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20520639%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference